Related Experiment Video
Updated: Feb 13, 2026
![Solid-phase Synthesis of [4.4] Spirocyclic Oximes](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F58508.jpg&w=3840&q=50)
Solid-phase Synthesis of [4.4] Spirocyclic Oximes
Published on: February 6, 2019
A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours
Keith Dredge1, Todd V Brennan2, Edward Hammond3
1Zucero Therapeutics, Brisbane, QLD, Australia. keith.dredge@zucero.com.au.
Background:
PG545 (pixatimod) is a novel immunomodulatory agent, which has been demonstrated to stimulate innate immune responses against tumours in preclinical cancer models.
Methods:
This Phase I study investigated the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of PG545 monotherapy. Escalating doses of PG545 were administered to patients with advanced solid malignancies as a weekly 1-h intravenous infusion.
Results:
Twenty-three subjects were enrolled across four cohorts (25, 50, 100 and 150 mg). Three dose-limiting toxicities (DLTs)-hypertension (2), epistaxis (1)-occurred in the 150 mg cohort. No DLTs were noted in the 100 mg cohort, which was identified as the maximum-tolerated dose. No objective responses were reported. Best response was stable disease up to 24 weeks, with the disease control rate in evaluable subjects of 38%. Exposure was proportional up to 100 mg and mean half-life was 141 h. The pharmacodynamic data revealed increases in innate immune cell activation, plasma IFNγ, TNFα, IP-10 and MCP-1.
Conclusion:
PG545 demonstrated a tolerable safety profile, proportional PK, evidence of immune cell stimulation and disease control in some subjects. Taken together, these data support the proposed mechanism of action, which represents a promising approach for use in combination with existing therapies.
Insights
Pixatimod (PG545) shows a tolerable safety profile and stimulates innate immune responses in patients with advanced solid tumors. Further research is warranted for combination therapies.
Area of Science:
- Immunology
- Pharmacology
- Oncology
Background:
- Pixatimod (PG545) is a novel immunomodulatory agent.
- Preclinical models show PG545 stimulates innate immune responses against tumors.
Purpose of the Study:
- Investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PG545 monotherapy in patients with advanced solid malignancies.
Main Methods:
- Phase I study with escalating doses of PG545 (25, 50, 100, 150 mg) administered as weekly intravenous infusions.
- Twenty-three subjects were enrolled across four dose cohorts.
- Safety, tolerability, PK/PD, and preliminary efficacy were assessed.
Main Results:
- Maximum-tolerated dose identified as 100 mg; dose-limiting toxicities (hypertension, epistaxis) occurred at 150 mg.
- 38% disease control rate observed; best response was stable disease up to 24 weeks.
- Pharmacodynamic data showed increased innate immune cell activation and elevated plasma cytokines (IFNγ, TNFα, IP-10, MCP-1).
Conclusions:
- PG545 demonstrates a tolerable safety profile, proportional pharmacokinetics, and evidence of immune cell stimulation.
- Disease control was observed in some subjects, supporting its mechanism of action.
- PG545 represents a promising approach for combination therapy in cancer treatment.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Bioavailability Study Design: Healthy Subjects Versus Patients
Phase Diagrams
Metallic Solids
All metallic solids exhibit high thermal and electrical conductivity, metallic luster, and malleability....
Structures of Solids
Phase Transitions

